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In this investigation we have explored the relationship between the weak allogenicity of cardiac
myocytes and their capacity to present allo-antigens by examining the ability of a human cardiac
myocyte cell line (W-1) to process and present nominal antigens. W-1 cells (HLA-A*0201 and
HLA-DR b1*0301) pulsed with the inﬂuenza A matrix 1 (58-66) peptide (M1) were able to serve as
targets for the HLA-A*0201 restricted CTL line PG, speciﬁc for M1-peptide. However, PG-CTLs were
unable to lyse W-1 target cells infected with a recombinant vaccinia virus expressing the M1 protein
(M1-VAC). Pretreatment of these M1-VAC targets with IFN-g partially restored their ability to process
and present the M1 peptide. However, parallel studies demonstrated that IFN-g pretreated W-1’s could
not process tetanus toxin (TT) or present the TT(830-843) peptide to HLA-DR3 restricted TT-primed
T cells. Semi-quantitative RT-PCR measurements revealed signiﬁcantly lower constitutive levels of
expression for MHC class I, TAP-1/2, and LMP-2/7 genes in W-1s that could be elevated by
pretreatment with IFN-g to values equal to or greater than those expressed in EBV-PBLs. However,
mRNA levelsfor thegenesencoding MHC class II, Ii, CIITA, and DMA/B were markedly lower in both
untreated and IFN-g pretreated W-1s relative to EBV-PBLs. Furthermore, pulse-chase analysis of the
corresponding genes revealed signiﬁcantly lower protein levels and longer half-life expression in W-1s
relative to EBV-PBLs. These results suggest that weak allogenicity of cardiac myocytes may be
governed by their limited expression of MHC genes and gene products critical for antigen processing
and presentation.
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INTRODUCTION
The molecular basis for chronic immune-mediated
rejection of solid human organ allografts continues to be
deﬁned (Hayry et al., 1995). In the case of cardiac
allografts, such chronic rejection is associated with loss of
myocytes which is reasoned to be secondary to lysis
mediated by donor speciﬁc “alloactivated” host derived
graft inﬁltrating lymphocytes (GIL’s) (Duquesnoy and
Demetris, 1995). It is now established that in order for
T cell activation to occur by either the direct or
indirect pathway at least two signals are required
(Bretscher, 1992). The ﬁrst signal is engendered by
cognateinteractionsbetweentheTCRonresponderTcells
and the appropriate peptide bearing MHC molecules
displayed on the surface of the allostimulator cells.
The second signals develop and act synergistically with
the ﬁrst signal and are mediated by the engagement of cell
surface expressed cellular adhesion and co-stimulatory
molecules (CAM’s/CSM’s) with their respective ligands.
Some of these CAM’s/CSM’s and their ligands are
constitutively expressed and others are induced by agents
such as cytokines. The quality and density of these
receptors and their cognate ligands that comprise
CAM’s/CSM’s expressed by allogeneic cells have been
shown to inﬂuence the type and relative strength of the
second signals generated (De Franco and Coffman, 1995).
In addition to the requirement for these two signals, data
has been presented to support the concept that the strength
(magnitude) of the allo-immune response is in part a
reﬂection of the number of antigen speciﬁc responder
T cell clones that become activated following recognition
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the stimulator cells (Warrens, 1994). This concept implies
that a certain threshold frequency of T cell clones must be
activated for an allogeneic response to be measured by
conventional techniques. Furthermore, detectable host
T cell alloproliferative responses become dependent on
the diversity of peptides that are presented by MHC
molecules on the stimulator cells within the allograft.
Therefore, the inherent limitations of a given cell lineage
to induce allogeneic immune responses (allogenicity) may
be dictated by the intrinsic ability of that cell to process
and present diverse sets of antigenic peptides.
However, the intrinsic abilities of cells comprising the
allograft to process and present antigenic peptides may
vary with their physiological, tissue lineage, or develop-
mental status. These characteristic potentials are most
likely manifested in the differential regulation and
expression of genes involved in the processing and
presentation of antigenic peptides as well as the synthesis,
transport and assembly of MHC Class I/II molecules to the
cell surface. Besides the MHC molecules, these include
but are not limited to the genes that encode CIITA, Ii,
TAP-1/2, LMP-2/7 and DMA/B (Neefjes, 1995; Mach
et al., 1996). We have previously proposed that cells
derived from distinct tissue lineages may be categorized as
non-professional, semi-professional and professional
antigen presenting cells (APC) based on their relative
abilities to process and present antigens (Sundstrom and
Ansari, 1995). This view is supported by our data derived
from a series of studies utilizing primary cultures of
various lineages of human cells including fetal human
cardiac myocytes (FHCM’s) and the surrogate FHCM cell
line termed W-1 (Wang et al., 1991). Our laboratory has
shown that neither FHCM’s nor the surrogate FHCM cell
line, W-1, when pretreated with IFN-g are able to induce
primary or to trigger secondary alloresponses invitro.This
deﬁcient allogenicity is not secondary to the lack of
expression of stable peptide-associated MHC Class 1/II,
the residual effects of IFN-g, or the elaboration of
suppressive cytokines, e.g. TGF-b (Ansari et al., 1995a).
Furthermore, W-1s do express functional costimulatory
molecules, e.g. LFA-3, and ICAM-1, yet they are still
unable to induce alloproliferative responses in resting
T cells even after their reconstitution with a human
glycosyl-phosphatidylinositol (GPI)-anchored B7-1
molecule (GPI-B7-1, manuscript in preparation). There-
fore, in this investigation we chose to examine and
compare the abilities of W-1s and EBV-PBLs to process
and present nominal antigens to primed class II and class I
restricted T cells. Our data revealed that in contrast to
EBV-PBLs, IFN-g pretreated MHC Class II expressing
W-1s incubated with TT antigen or pulsed with the
antigenic P2 peptide were unable to induce proliferative
responses in TT primed T cells. When similar experiments
were performed for the MHC Class I processing and
presentation pathways, W-1s were able to present
exogenoulsy added inﬂuenza A M1 peptide to the
peptide-speciﬁc CTL cell line, PG. However, W-1s were
able to process and present the native inﬂuenza A matrix 1
protein only after pretreatment with IFN-g. These results
prompted us to examine the regulation of genes involved
in the MHC Class I/II antigen processing and presentation
pathways in the W-1 cell line. We compared the levels of
expression of MHC genes and their gene products in the
W-1s, before and after pretreatment with IFN-g, with
constitutive levels in other professional and non
professional APCs to see how they might correlate with
their abilities to process and present antigenic peptides.
Our data suggest that the functional limitations of W-1s to
process antigenic peptides for presentation by MHC
Class I or by Class II are related to both their relatively
weak gene expression within the MHC locus and the
prolonged turnover time of the corresponding gene
products. The results of these investigations constitute
the basis of this report.
MATERIALS AND METHODS
Preparation and Culture Conditions of Lymphocytes
and Cell Lines
The surrogate FHCM cell line, W-1, was derived by
SV40 large-T-antigen induced transformation of an
enriched population of FHCM as previously described
(Wang et al., 1991). This cell line remains phenotypically
stable with respect to MHC expression, cardiac myosin
content, expression of insulin-like growth factor
receptor type 1, thrombin receptors, P2Y purinoceptors,
b-adrenergicreceptors,andreactivitywith immunochemi-
cal reagents that distinguish this cell line as being of
cardiacmyocyteoriginandnotofendothelial,epithelial,or
smooth muscle origin. This cell line has been serologically
typed for MHC Class I as HLA A2.A30, B17.B18;
C3.C5,Bw4.Bw6 and molecularly typed for MHC Class II
as DRb1*0301, DRb 1*1302, DRb 3*0202, DRb 3*0301,
and DQb1*0201 (Table I). The adherent W-1 cell line was
cultured in HM-1 medium. HM-1 medium consists of
equal volumes (38%) of BME and HAM’s F10 nutrient
mixture, 5% human AB serum, 20% FBS, 2mM
L-glutamine, bovine insulin (50mg/ml, Sigma) and
gentamicin (50mg/ml). All sera were heat-inactivated at
568C for 1h prior to use. Primary and immortalized human
lung (pulmonary) microvascular endothelial cells
(Lawrence et al., 1995; Waite-Rees et al., 1996) and
primary and immortalized human dermal microvascular
endothelial cells (Ades et al., 1992) that were used in
control experiments were grown and maintained as
previously described. Donor peripheral blood mono-
nuclear cell (PBMC) responders were isolated by gradient
centrifugation on LSM (Organon Teknika, Durham, NC)
as previously described (Ansari et al., 1995b). Preparation
of enriched CD3
þ populations of responders was
accomplished by subjecting PBMCs to negative selection
over Human T-cell enrichment columns (R&D systems).
The enriched T cell populations were shown to be greater
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þ by ﬂow microﬂuorometric analysis (FMF)
using FITC-conjugated antibodies directed against human
CD3 (data not shown). As a source of autologous
stimulator cells, an Epstein Barr Virus transformed cell
line was derived from this same donor’s (LW) peripheral
blood lymphocytes by incubating isolated PBMCs in vitro
with supernatant ﬂuid from the B95-8 marmoset cell line
(Ansari et al., 1995b). Another EBV-PBL cell line
developed from donor JS, who also shares HLA-DR
identity with W-1 (HLA-b1*0301, HLA-A2*0201), was
used in some experiments for the purpose of control. For
CTL experiments, the human PG CTL line was generated
aspreviously described(Gotchetal.,1987).This CTL line
recognized the HLA-A2*0201 restricted inﬂuenza A
matrix 1 epitope GILGFVFTL (corresponding to residues
58-66). The human lymphoblastoid cell line PG that was
used as a source of autologous APCs in CTL experiments
was grown in RPMI 1640 with 10% FCS.
Preparation of Synthetic Peptides
The peptides listed in Table II were prepared by solid-
phase synthesis on an Applied Biosystems (Foster City,
CA) model 430A peptide synthesizer with phenyl-
acetamidomethyl copoly (styrene/divinyl benzene) resins
and tert-butyloxycarbonyl (t-Boc) amino acid protection
strategies. Some peptide preparations were N-terminally
biotinylated via a two b-alanine spacer using the linking
agent hydroxybenzotriazol (HOBT). The crude peptides
were puriﬁed by microbore reversed-phase high-
pressure liquid chromatography (HPLC) on an Aquapore
OD-300C18 silica columns (1 by 250mm) with a linear
gradient of acetonitrile in 0.1% aqueous triﬂuoroacetic
acid and stored at 2208C in lyopholized form as
previously described (Shafer et al., 1993). Due to
the hydrophobic characteristics of the P2 peptide,
solubilization with dimethyl sulfoxide (,1% v/v) was
necessary for use in vitro. Therefore, for experiments
using the soluble P2 peptide, control cultures were
suspended in media containing the same concentration of
DMSO. The inﬂuenza A matrix 1 (58-66) peptide,
GILGFVFTL, was synthesized manually using fmoc
chemistry. Cleavage and deprotection was done with TFA.
The peptide was puriﬁed by ether precipitation followed
by reversed-phase HPLC and was checked for purity
(.95%) by HPLC. This peptide was also solubilized in
DMSO for experiments as described above.
Proliferation Assays
All in vitro cell proliferation assays were performed in
triplicate wells in a volume of 0.2ml of complete media in
round-bottomed 96-well tissue culture plates. Complete
culture media consisted of RPMI 1640 with 10%
FBS, 2mM L-glutamine, and gentamicin (50mg/ml).
Cocultures were incubated at 378C and 7% CO2 for ﬁve
days, then each well was pulsed with 1mg Ci/well of
methyl-
3H thymidine (2Ci/mmol, NEN, Boston, MA) for
16h before harvesting and counting for 1min on a LKB
liquid scintillation counter.
Preparation of APC’s and Antigen-primed T Cells
For experiments measuring the abilities of cells to process
and present TT antigen, LW-EBV-PBL or the W-1 cells
(HLA-DRb1*0301) were incubated overnight in complete
media containing TT (1Lf/ml). They were then washed
twice, suspended at 10
6cells/ml (W-1’s) or 2£
106 cells=ml (LW-EBV-PBL) in complete media, then
g-irradiated (80Gy). A total of 5 £ 104 (W-1’s) or 10
5
TABLE I Allelic Classiﬁcation of HLA speciﬁcities for APCs and responder cells
A. Molecular classiﬁcation of MHC class II speciﬁcities
APC/ responder DRB1a DRB1b DRB3a DRB3b DRB5b DQB1a DQB1b
W-1 0301 1302 0202 0301 0201
LW PBMC 0301 1301/4 0101 0201 0603
JS-EBV-PBL 0301 1501/3/4 0202 0101 0201/2 0602/3
B. Serological classiﬁcation of MHC class I speciﬁcities
APC Aa Ab APC Bb
W-1 2 30 17 18
LW-EBV-PBL 2 24 8 62
JS-EBV-PBL 2 30 18 51
TABLE II Synthetic peptides
Synthetic peptide Sequence HLA-restriction(s) References
TT 830-843 (P2) QYIKANSKFIGITE DR3, DR1, DRw15(2), DRw18(3), DR4Dw4,
DRw11(5), DRw13(w6), DR7, DRw8, DR9,
DRw52a, and DRw52b
(Panina-Bordignon et al.,1
989; O’Sullivan et al., 1991;
Reece et al., 1993)
Inﬂuenza A matrix
1 peptide 58-66 (M1)
GILGFVFTL A2 (Bednarek et al., 1991)
Inﬂuenza HA (306-318) PKYVKQNTLKLAT DR1, DR2, DR5, DR7 (O’Sullivan et al., 1991;
Weber et al., 1996)
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then mixed 1:1 (v/v) with 10
5 unfractionated LW-PBMCs
or T cell enriched LW responders and cocultured as
described above. For experiments measuring the abilities
of cells to present the P2 antigenic peptide, the appropriate
APCs were suspended at 10
7/ml in serum free
PBS containing 100mg/ml synthetic P2 and then
incubated for 2h at 378C, then washed twice before
placing in coculture with TT primed T cells. TT primed
cells were prepared from an individual donor (LW) who
shares HLADRb1*0301 speciﬁcity with the W-1 cell line
(Table I) and who had also received a recent (2 weeks)
tetanus booster vaccination. Controls included with each
experiment consisted of measurements of the comparative
proliferative responses of unfractionated LW-PBMCs and
highly enrichedT cells that were collectedbefore and after
the TT immunization. In addition, antigen speciﬁcity of
the response was determined with the use of KLH pulsed
APCs. The results veriﬁed that the proliferative responses
of TT-primed responders were secondary and speciﬁc for
TT antigen (data not shown).
Cytotoxicity Assays
The CTL activity of a CD8
þ, HLA-A*0201 restricted
human CTL cell line (PG) speciﬁc for the inﬂuenza A
matrix 1 peptide, M1, was measured in a standard
51Cr
release assay as previously described (Morrison et al.,
1992). Target cells consisting of autologous PG lympho-
blastoid cells or W-1s with and without pretreatment with
IFN-g were incubated at 378C with peptide M58-66 at
5mMormocktreatedfor1h,thenwashedandlabeledwith
100mCi of
51Cr for 1h at 378C. For other experiments,
target cells were infected with recombinant vaccinia
viruses M1-VAC or NP-VAC at 10 plaque-forming-units
(PFU) per cell for 90min. The target cells were then
washed and incubated for 18h in culture medium before
labeling with
51Cr as described. M1-VAC and NP-VAC
encode the full length inﬂuenza A matrix 1 protein and
the full length inﬂuenza A nucleoprotein, respectively.
These constructs were generated as previously described
(Gotch et al., 1987; Shafer et al., 1993).
For the CTL assay, a total of 5 £ 103 targets were
incubated with various effector-to-target ratios (E:T),
medium alone (spontaneous release), or 5% Triton X-100
(maximum release). After 5h the plates were spun down
and the radioactivity (average cpm) from each of duplicate
wells was determined. The percentage of speciﬁc lysis was
calculated as [(release by CTL targets) 2 (spontaneous
release)] £ 100/[(maximum release) 2 (spontaneous
release)]. The spontaneous release was consistently below
15%. The expression of vaccinia encoded genes in targets
was checked by monitoring b-galactosidase expression
following NP-VAC infection. A total of 2 £ 105 infected
cells were lysed with H2O then X-Gal was added to a ﬁnal
concentration of 6mg/ml. The kinetic degradation of
X-Gal by infected W-1 and PG target cells were identical
(data not shown).
Quantitation of the Expression of Genes Involved in
the MHC I/II Antigen Processing and Presentation
Pathways by Semi-quantitative RT-PCR
Quantitation of the relative constitutive and cytokine
induced levels of mRNA expressed by the human MHC
class I/II genes CIITA, Ii, DMA, DMB, LMP-2, LMP-7,
TAP-1 and TAP-2 from thevarious tissue lineage cell lines
was determined using a semi-quantitativeRT-PCR method
established by our laboratory (Villinger et al., 1995).
RNA Isolation
Total cellular RNA was isolated from 2 £ 106 cells from
each tissue lineage using a guanidium thiocyanate-phenol
chloroform single step method. A total of 20mg of carrier
salmon sperm DNA was then added to each of the RNA
samples to facilitate precipitation with isopropanol.
Reverse Transcription of Cellular mRNA
Reverse transcription (RT) of RNA isolated from each
sample dilution was performed in the following manner.
Air-dried RNA pellets were resuspended in 20mlo f
reverse transcription mixture (pH 8.5) consisting of
50mM Tris, 6mM MgCl2, 40mM KCl, 10mM DTT,
0.01% Nonidet P-40, 50mM random hexamers, 25mM
deoxynucleotide triphophates (dNTP), 3U RNasin,
and 30U murine leukemia virus reverse transcriptase
(Promega, Madison, WI). Reverse transcription of cellular
mRNA into ﬁrst strand cDNA was allowed to proceed at
room temperature for 10min and then at 428C for
1h followed by heat inactivation at 958C for 5min.
The efﬁciency and sensitivity of each RT reaction
was determined by ampliﬁcation of GAPDH transcripts
(25 cycles).
PCR Ampliﬁcation
Oligonucleotide primer pairs (Table III) speciﬁc for each of
thehumanMHCClassI/IIgeneswerepreparedaccordingto
published gene sequences. Ampliﬁcation of aliquots of the
cDNA reverse transcribed from each dilution of the sample
RNA was performed in 50ml of a reaction mixture
containing 2.5mM MgCl2, 0.125mM of each dNTP
(dATP, dCTP, dGTP, and dTTP), 100ng of each primer
and 1U of Taq polymerase in 1X Taq buffer (Perkin Elmer,
Norwalk, CT). Samples were overlaid with mineral oil,
(Sigma, St. Louis, MO) then subjected to 30 cycles of
denaturation (958C), annealing (608C), and elongation
(728C) in a Perkin-Elmer thermocycler. Semi-quantitative
evaluation of the ampliﬁed product was performed
by parallel ampliﬁcations of ten-fold serial dilutions (10
26
to 10
21 copies) of each respective cloned gene. Ampliﬁca-
tion products were separated by agarose-gel electro-
phoresis, blotted onto nylon membranes, then hybridized
with digoxigenin (DIG)-labeled (Boehringer Mannheim
Biochemical) internal oligonucleotide (Table III).
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was accomplished by enzyme-linked immunoassay using a
nonradioactive DIG DNA labeling and detection kit and by
chemiluminescence (Boehringer Mannheim Biochemical).
Semi-quantitative estimates of sample mRNA were
performed by comparing the signals obtained from the test
samples with those from serial dilutions of the cloned
fragments. The signals were found to follow a linear range
between 10
0 and 10
9 copies.
Pulse Chase Experiments
Cells were metabolically labeled as follows. Conﬂuent
cultures were washed once in DPBS then incubated for 2h
at378Cincys
-/met
-RPMI.Thecellswerethentrypsinized,
washedtwiceandadjustedto4 £ 106=mlinwarmcys
-/met
-
RPMI. For continuous biosynthetic labeling, [
35S]-met
trans-label (Amersham) was added (at 0.25mCi/ml) and
thecellswereculturedfor2hat378Cat7%CO 2.Fortimed
experiments, cells were pulsed with [
35S]-met trans-label
for2hthenchasedwithRPMIcontaininganexcess(2mM)
ofcoldmetforappropriatetimeintervals.Thelabeledcells
were then centrifuged and washed twice in RPMI and then
resuspended at 5 £ 107=ml in lysis buffer (consisting of
100mM Tris–Cl pH 8.0, 140mM NaCl, 0.25% NaN3,1 %
Triton X-100, 1% bovine hemoglobin, 5mM iodo-
acetamide, 1% aprotinin, 4mM phenylmethylsufonyl
ﬂuoride (PMSF), 5mM phenanthroline, 15mM pepstatin,
560mMN - t o s y l - L-Phenylalanine chloromethyl ketone
(TPCK), 5mM benzamidine, 6.6mM N-ethyl maleimide
(NEM), 10mM leupeptin, 270mM N-tosyl-L-lysine
chloromethyl ketone (TLCK), and 10mM EDTA in
TSA) and incubated for 60min at 48C. To facilitate
cytolysis, the cell mixture was reﬂuxed through a 27g
needle at the end of the incubation. The cell lysates were
then centrifuged at 12,000g for 10min (at 48C) in a
microfuge. The supernatant ﬂuid was then precleared by a
2h incubation at 48C with quenched protein-A sepharose
beads. The sepharose beads were separated and removed
from the precleared lysates by centrifugation. Immuno-
precipitation of solubilized MHC antigens was performed
using speciﬁc antibodies (listed in Table IV) coupled to
protein-Asepharosebeads.Brieﬂy,40mlofa50%slurryof
Ab-sepharose in dilution buffer (1% Triton X-100 and 1%
BovinehemoglobininTSA,pH8.0)wasaddedto100mlof
preclearedlysatesolutionand310mlofdilutionbuffer.The
reaction mixture was gently mixed on a rotator for 1.5h at
48C. Afterwards, the mixture was washed twice in dilution
buffer, once in 50mM Tris (pH 8.0) and once in 50mM
Tris–Cl (pH 6.8). The protein A-sepharose bound
immunoprecipitates were then pelleted, dissociated by
boiling for 4min in 40ml of 2X SDS sample buffer,
fractionated by SDS-PAGE, then visualized and quanti-
tatedwithaBioRadGS525molecularimagersystemusing
an [
35S]-phosphoimager enhancement screen.
Peptide Binding Assays
Binding of biotinylated P2 peptides to HLA DR b1*0301
expressing W-1s or LW-EBV-PBLs was determined in
TABLE III List of oligonucleotide primers used for ampliﬁcation in LDA-RT-PCR for MHC ClassI/ II gene mRNA transcripts
Oligo Primer site Sequence (50 to 30) Size of ampliﬁed fragment (bp)
CIITA 50* GCTTGGCTCGTGTGCTTCCG 515
30† TCAGCAGAGCAAGATGTGGTTCA
IP
‡ TCCACATCGCCAGAGTCTCC
Ii 50 TGGTGACTCTGCTCCTCGCTG 515
30 CAGATCCTGCTTGGTCACACC
IP CTTTCGGTGGAGCGTCAGTGG
DMA 50 CTAAAAGCTGGTTGGTAGCTCC 859
30 GCTGGCATCAAACTCTGGTCTG
IP AGCATCTCCCTGTTCCTGAGCC
DMB 50 GGCATCTTTACAGAGCAGAGCATGA 647
30 GGTGTCCAGTCCCGAAGGATG
IP GGCTAAATGGGAGAGGGTCTGGT
LMP-2 50 GCACCAACCGGGGACTTACC 413
30 TGAAGCGCCTGCACTCCTCG
IP GTTCAGCTGCTGATGCCCAA
LMP-7 50 TCTAGTCTTCTGGTTGAAGCTGCG 509
30 CGAGTCCCATGTTCATCCACGT
IP GCTGCCGACACTGAAATACGTT
TAP-1 50 CCTCTCGCTGTTCCTGGTCC 703
30 GATTCCCACTTTCAGCAGCATACC
IP GCAGGACAGCCCCAAACACC
TAP-2 50 AGCAGGACCAGGTGAACAACAA 654
30 CAAACCTGCGAACGGTCTGC
IP CGCAAGAGCACATTGGCATTTA
*Sense primer.
†Anti-sense probe.
‡Internal probe (digoxigenin-labeled).
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7
W-1s were suspended in a volume of 0.5ml of RPMI
containing 20% FBS, 2mM L-glutamine, 50mg/ml
gentamicin, and 10mM P2-biotin then incubated for 8h
at 37 EC in humidiﬁed 7% CO2 atmosphere. After three
washes in 10ml of serum-free RPMI, the cell preparations
were lysed, and immunoprecipitation with anti-HLA-DR
bound to protein A sepharose beads was performed as
described above. The immunoprecipitates were then
washed twice in dilution buffer, once in 50mM Tris-
buffered saline, and then once in Tris–Cl pH 6.8. Next,
a volume of 500ml of streptavidin europium (Wallac,
Turku, Finnland) diluted 1:500 in assay buffer was added
to the washed samples which were then incubated on a
rocker for 1h at 48C. The samples were then washed 7X in
50mM Tris buffered saline. The washed pellets were then
suspended in a volume of 100ml of enhancement
buffer and incubated on a rocker for 15min at room
temperature. The samples were then transferred to a 96
well cross-talk free microtiter plate (PE) and time-
resolved Eu-phosphorescence was measured using a PE
LS50B luminescence spectrophotometer (Perkin Elmer,
Norwalk, CT).
RESULTS
Inability of MHC Class II (HLA-DRb1*0301)
Expressing W-1 Cell Line to Process and/or Present
TT Antigen and the TT (830-843) Immunodominant
HLA-DRb1*0301-binding Peptide, P2
To evaluate the ability of W-1 cells to process exogenous
antigen for presentation by MHC Class II, IFN-g
pretreated W-1s or autologous LW-EBV-PBLs were
incubated with TT antigen as described, then used in
proliferation assays with previously TT primed LW
responder cells. While TT-primed unfractionated
LW-PBMCs or puriﬁed T cells showed marked proli-
ferative responses to TT antigen processed and presented
by LW-EBV-PBLs, they showed no signiﬁcant prolifera-
tive response to (identical) MHC class II expressing W-1s
similarly pulsed with TT antigen (Fig. 1). The speciﬁcity
TABLE IV Reagents used for immunoprecipitation of MHC Class II gene products involved in antigen processing and presentation
Antibody speciﬁcity (human) Clone Host species/type Source
Amount used per 5 £ 106
cell equivalents
MHC Class I W6/32 Mouse/Mab ATCC 30ml neat
MHC Class II CR3/43 Mouse/Mab DAKO 15ml neat
Invariant chain Pin-1 Mouse/Mab Dr. P. Cresswell 15ml neat
LMP-2/LMP-7 Rb/Polyclonal Dr. Patel/McDevitt 30ml neat
(RING12/RING10)
TAP-1/TAP-2 Rb/Polyclonal Dr. P. Cresswell 5mg/ml
(RING4/RING11)
DMB (RING7) Rb/Polyclonal Dr. P. Cresswell 10ml 1:4
FIGURE 1 MHC class II restricted responses to TT antigen or P2 antigenic peptides presented by HLA DRb1*0301 APCs. The abilities of IFN-g
pretreated W-1s and LW-EBV-PBLs to process and present TT antigen or to present synthetic P2 antigenic peptide to TT-primed unfractionated LW-
PBMCs or puriﬁed LW-T cells were compared in 5 day proliferation assays as described in “Material and Methods” Section. Incorporation of [
3H]-
thymidine was measured as the average CPM in triplicate wells. These results are representative of three separate experiments.
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absence of proliferation of LW-PBMCs in coculture with
the control antigen KLH.
The ability of IFN-g pretreated W-1s to present the
synthetic HLA DR3-binding TT immunodominant
peptide, P2, was also examined in these same sets of
experiments. The APCs (IFN-g pretreated W-1s or
LW-EBV-PBLs) were pulsed with the immunodominant
HLA-DRb1*0301-binding TT 830-843 peptide (P2) as
described. Again, we found marked proliferative
responses by both the unfractionated PBMCs and the
highly enriched T cells of LW to P2 peptide presented by
autologous APCs while no signiﬁcant proliferation was
observed in aliquots of the same responder cells to the P2
peptide presented by MHC Class II expressing P2-pulsed
W-1’s (Fig. 1). The failure of W-1 cells to induce antigen
speciﬁc T cell proliferation was not secondary to dose of
antigen (TT or P2) or response kinetics (data not shown).
Furthermore, APC’s were clearly required since puriﬁed
T cells did not proliferate when cultured alone with TTor
the P2 peptide without APC’s. Finally, non IFN-g
pretreated W-1 cells when pulsed with similar doses of
TT or the P2 peptide also failed to induce signiﬁcant T
cell proliferation (data not shown).
Ability of W-1 Cells to Process and Present Inﬂuenza
a Matrix Peptide (M58-66) to HLA-A2 Restricted
T Cells
MHC class I presentation of the deﬁned inﬂuenza A
matrix 1 protein was evaluated in a standard CTL assay as
described in the “Materials and Methods” section.
Vaccinia constructs containing the inﬂuenza A matrix 1
protein (M1-VAC) or the inﬂuenza A nucleoprotein (NP-
VAC) were used to infect target cells for antigen loading
into the class I processing pathway. Since W-1 cells
constitutively express low but detectable levels of MHC
Class I, we ﬁrst examined the ability of W-1s without
pretreatment with IFN-g, to serve as targets for the PG
CTL line speciﬁc for the M1 58-66 peptide presented by
HLA-A*0201. As shown in Fig. 2A, W-1s infected with
M1-VAC or a vaccinia construct containing the inﬂuenza
A nucleoprotein (NP-VAC) as a negative control, were
unable to be lysed by the PG CTL line. On the other hand,
W-1s pulsed with the synthetic M1 58-66 antigenic
peptide showed an average speciﬁc lysis between 40 and
50%, which was comparable to the results obtained when
the autologous PG-EBV-PBL targets were used (Fig. 2C).
When the W-1 targets were pretreated with IFN-g (prior to
infection with MI-VAC), an average speciﬁc lysis ranging
from 20 to 30% was observed in the M1-VAC infected
targets (Fig. 2B). The CTL response was M1 peptide
speciﬁc since no lysis was observed in the control NP-
VAC infected IFN-g pretreated W-1 target cells. These
values reﬂect a net speciﬁc lysis of approximately 50% of
those obtained with PG-EBV-PBL targets infected with
MI-VAC (Fig. 2C). The inability of W-1s to process and
present M1 peptides for class I was shown not to be due to
the failure of vaccinia to infect target cells since the
presence of b-galactosidase in the cytosol of W-1 targets
infected with control vaccinia constructs loaded with this
indicator was conﬁrmed colorimetrically by the degrada-
tion of 5-bromo-4chloro-3indoyl b-D-galactoside (X-gal)
in lysed
51Cr-labeled W-1 targets cells (data not shown).
Although, this is not a quantitative measurement of the
level of expression of the inﬂuenza A matrix 1 protein or
nucleoprotein within the cytosols of the vaccinia infected
cells, the amount of substrate metabolized was essentially
equivalent in all three target cell groups.
Expression of Genes Encoding Components of
the MHC Class I/II Antigen Processing Pathways
Within the MHC Class II locus, located on the short arm of
human chromosome 6 are the genes which encode the
MHC Class I heavy chain, the Class II a and b chains, and
critical cellular components for the Class I and the Class II
antigen processing pathways. Two subunits of the 20s
FIGURE 2 MHC class I restricted responses to inﬂuenza A matrix 1
protein the synthetic M1 (58-66) antigenic peptide presented HLA-
A*0201 target cells. The abilities of W-1s (A), IFN-g pretreated W-1s
(B), and PG-EBV-PBLs (C) to process and present inﬂuenza A matrix 1
protein or to present M1 (58-66) antigenic peptide and serve as targets for
the M1 peptide-speciﬁc cloned PG CTL cell line were compared in
standard 5h CTL assays as described in “Material and Methods” section.
These results are representative of three separate experiments. To
introduce antigen into the cytosol for processing by the class I pathway,
target cells were infected with vaccinia constructs containing the
inﬂuenza A matrix 1 protein (M1-VAC) or the inﬂuenza A nucleoprotein
(NP-VAC). For other experiments target cells were incubated with the
synthetic inﬂuenza A M1 (58-66) peptide before assaying for speciﬁc
lysis by PG CTLs.
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transporters of antigenic peptides, encoded by TAP-1 and
TAP-2, together process and transport endogenous
antigens into the ER where they associate with nascent
MHC class I molecules, which are subsequently
transported to and expressed on the cell surface
(Lehner and Cresswell, 1996; York and Rock, 1996).
Though the role of DMA and DMB continues to be
elucidated, DM has recently been shown to be involved in
the exchange of processed antigenic peptides for
processed invariant chain peptide (CLIP) on nascent
MHC Class II molecules within the compartment for
peptide loading (CPL) (Denzin and Cresswell, 1995;
Sloan et al., 1995; Weber et al., 1996). Regulation of
MHC Class II gene expression is coordinated by the Class
II transactivator (CIITA) which is also located within the
MHC Class II gene locus (Chang and Flavell, 1995).
Although it is located on a separate chromosome, the gene
encoding Ii is co-regulated with expression of the MHC
Class II genes due to shared promoter/enhancer elements
(Nordeng and Bakke, 1994). Deﬁcient expression of any
of these genes has been shown to result in defective or
absentantigen presentation by MHC antigens(Machet al.,
1996). Therefore, in order to assess antigen processing and
presentation defects of the W-1 cell line from the
perspective of gene expression, mRNA levels for each of
these genes were determined by the semi-quantitative
PCR method described above.
The constitutive expression of mRNA for genes
involved in the class II antigen processing pathway were
below detectable levels in W-1s, a ﬁnding consistent with
the fact that W-1s do not constitutively express MHC class
II. When W-1s were pretreated with IFN-g to induce
maximum expression of MHC class II, the transcription
levels within the panel of class II genes were up regulated
to a range of values all less than those constitutively
expressed by the same genes in EBV-PBL controls.
Figure 3A depicts the relative levels of expression of
mRNA (copy equivalents) for MHC class II, CIITA, Ii,
DMA, and DMB in IFN-g W-1s as a percentage of the
corresponding mRNA levels found in EBV-PBL controls.
While mRNA levels in IFN-g W-1s relative to EBV-PBLs
are approximately 70 and 90% for DMB and DMA,
respectively, they are represented at levels between 50 and
60% for Ii and CIITA, and fall signiﬁcantly between 10
and 20% for MHC class II. These data suggest that
although IFN-g can up regulate transcription of multiple
genes critical to the class II processing pathway, the
markedly weak level of expression of MHC class II
mRNA most likely has the strongest inﬂuence (at the
transcriptional level) in limiting the ability of W-1s to
process and present antigenic peptides for MHC class II.
This interpretation is supported by results of FMF
FIGURE 3 Comparison of mRNA levels of genes in the MHC class I/II antigen processing and presentation pathways in different APCs. Semi-
quantitativemeasurementsofmRNAlevelofgenesinvolvedintheclassIIpathway(MHCII,CIITA,Ii,DMA,andDMB)andtheclassIpathway(MHC-1,
TAP-2,LMP-2,andLMP-7)weremadebyRT-PCRasdescribedin“MaterialsandMethods”section.ThelevelsofexpressionofmRNA(copyequivalents)
fromeach celllinetestedare expressedasa percentageofthe constitutive expressionofmRNAmeasuredintheEBV-PBLcontrols.(A)Relative levelsof
class II pathway gene expression for IFN-g W-1s. (B) Relative levels of class I pathway gene expression for W-1s and IFN-g W-1s. (C) Relative levels of
class I pathway gene expression for IFN-g W-1s, primary human dermal microvascular endothelial cells (HDMEC), and primary human lung
microvascularendothelialcells(HULEC).(D)RelativelevelsofclassIpathwaygeneexpressionforIFN-gW-1s,transformedHDMEC(HDMEC-T)and
HULEC’s (HULEC-T).
J.B. SUNDSTROM et al. 220(data not shown) and pulse chase studies (detailed below)
which conﬁrm that the amount of MHC class II protein
which is expressed on the cell surface or that can be
immunoprecipitated from lysates of IFN-g pretreated W-
1s is only 10% of those values relative to EBV-PBLs.
To measure gene transcription within the class I antigen
processing pathway, mRNA measurements of MHC
class I, TAP-1, TAP-2, LMP-2 and LMP-7 genes were
performed by RT-PCR as described. We have previously
shown that the expression of MHC class I on W-1’s cell
surface is up regulated by IFN-g (Ansari et al., 1994).
This ﬁnding is supported by measurements comparing
the levels of the class I speciﬁc mRNAs found in W-1s and
IFN-g pretreated W-1s (Fig. 3B). An interesting
observation was that IFN-g pretreatment resulted in
gene expression within W-1s that was approximately
equivalent to (MHC I, TAP-2, LMP-7) or exceeding
(TAP-1, LMP-2) that of EBV-PBLs. Since defects in
antigen processing and presentation for MHC class I have
been reported for several malignant and transformed cell
lines (Seliger et al., 1996), we chose (for a basis of
comparison) to include measurements of constitutive
levels of the speciﬁc mRNAs expressed in corresponding
sets of both primary (Fig. 3C) and (SV40 large T antigen)
transformed (Fig. 3D) microvascular endothelial cell
lines. Compared to primary dermal or lung microvascular
endothelial cells, the mRNA levels in W-1s were roughly
equivalent with the exception of MHC class I which was
slightly (but not signiﬁcantly) lower. When IFN-g
pretreated W-1s were compared with (SV40) transformed
dermal or lung microvascular endothelial cells, the level
of mRNA for MHC class I was even higher in the
immortalized cells than in the primary ECs. Thus, at least
for gene transcription, we found no evidence of inhibition
due to SV40 transformation.
Pulse Chase Analysis of Components of the MHC Class
I/II Antigen Processing Pathways
Having measured the relative levels of transcription of the
genes involved in antigen processing and presentation,
we next compared the relative levels and half lives of the
translation products of the same set of genes from IFN-g
pretreated W-1s with the corresponding gene translation
products from professional APCs. The antibodies used for
these studies (listed in Table IV) were chosen for their
ability to recognize and immunoprecipitate all the major
isoforms of the individual components examined in our
investigation: MHC I/II, Ii, LMP-7, TAP-1, TAP-2, and
DMB. Our results showed (Fig. 4A) that the levels of
immunoprecipitated gene products were much lower in
the IFN-g pretreated W-1 cell line, ranging from
FIGURE 4 Relative levels and half-lives of immunoprecipitated proteins involved MHC class I/II antigen processing and presentation in IFN-g W-1s
and EBV-PBLs. (A) The relative levels of expression of the translation products of MHC class I/II, Ii, DMB, TAP-1/2, and LMP-7 genes for IFN-g W-1s
and EBV-PBLs were determined by immunoprecipitation with speciﬁc antibodies (listed in Table IV) as described in “Materials and Methods” section.
The values for protein levels in IFN-g W-1s are expressed as a percentage of the corresponding constitutive levels measured in EBV-PBLs. (B) The
turnover rates (determined by pulse-chase analysis) for each of the immunoprecipitated gene translation products, expressed in half-lives (h), are
compared for IFN-g pretreated W-1s and EBV-PBLs. (C) The values for the half-lives of proteins immunoprecipitated in IFN-g pretreated W-1s
are expressed as a percentage of the corresponding constitutive values measured in EBV-PBLs.
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(for LMP-7) of the corresponding levels observed in an
equivalent number of JS-EBV-PBLs. Concomitantly, the
half lives of all the same components measured were
signiﬁcantly increased in the IFN-g pretreated W-1 cell
line compared with the EBV-PBL controls (Fig. 4B,C).
The values (based on the results of two separate
experiments) of the percent increases in half-lives ranged
from a low of approximately 180% for LMP-7 to a high of
330% for MHC Class I. Thus, the low levels of expression
together with the slow turnover rates support the concept
of a lethargic pace of antigen processing within the IFN-g
induced W-1 cell line and are consistent with the observed
functional defects in antigen presentation by W-1’s.
Evaluation of P2 Peptide Binding to HLA-DR3
The W-1 cell line and the LW-EBV-PBL cell line, which
were compared by their abilities to present P2 peptide to
TT primed LW T cells, both share HLA DRb1*0301
(as well as HLA DQb1*0201) speciﬁcities (Table I).
The potential of exogenously loaded P2 peptide to
speciﬁcally bind to HLA DR in these two cell lines was
conﬁrmed by the Eu-based peptide binding assay
described. A linear dose response to P2-peptide-MHC
complexing was observed with HLA-DR immunopreci-
pitated from LW-EBV-PBLs pulsed with a biotinylated
form of P2 peptide (Fig. 5A). In competitive inhibition
assays unbiotinylated native P2 peptide at 5 molar excess
was able to speciﬁcally inhibit binding of the biotinylated
peptide bound to MHC class II expressed by LW-EBV-
PBLs by approximately 50%, whereas the HLA-A*0201
binding M1 (58-66) peptide or the HLA DR1 binding HA
(306-318) peptide were unable to inhibit P2-B peptide
binding even when used at 10 molar excess concentrations
(Fig. 5B). Similar results were obtained with parallel
peptide-binding experiments performed with IFN-g
pretreated W-1 cells (Fig. 5C).
DISCUSSION
In this study we have shown that the W-1 cell line is not
able to effectively process and present the DR3 restricted
TT(830-843) antigenic peptide, P2, and has only a
moderate ability to process and present the HLA-A2
restricted inﬂuenza A M1 peptide. Our interest in pursuing
this investigation was based on our previous ﬁndings that
neither the W-1 cell line nor FHCM’s induce primary or
secondary alloresponses in T cells even after pretreatment
with IFN-g to induce their expression of MHC Class II
(Ansari et al., 1995a). Therefore, our focus in this study
has been to explore the connections between the inability
of W-1 cells to induce alloresponses and their intrinsic
ability to process and present nominal antigens. It has been
demonstrated that at least some T cell clones are capable
FIGURE5 Bindingofthe synthetic TT (830-843)antigenicpeptide(P2) to MHCclass II onAPCs.The bindingof a biotinylatedformofthe P2peptide
(P2-B) to HLA DRb1*0301 expressed on IFN-g W-1s or LW-EBV-PBL controls was measured by the europium peptide binding assay described in
“Materials and Methods” section. (A) Dose response of P2-B to LW-EBV-PBLs. (B) Competitive inhibitionof P2-B binding to LW-EBV-PBLs by native
P2 but not the HLA A*0201-binding peptide M1 (58-66) or the HLA DR1 binding peptide HA (306-317). (C) Levels and competitive inhibition of P2-B
binding to IFN-g W-1s by native P2 peptide.
J.B. SUNDSTROM et al. 222of directly recognizing allo-MHC independent of bound
peptide (Elliott and Eisen, 1990; Warrens, 1994).
However, there is growing acceptance of the view that
individual T cell clones recognizing multiple allogeneic
determinants, formed by single processed oligomeric
peptides complexed with MHC Class I/II molecules and
displayed on the surface of the APC, determines the high
precursor frequency of alloreactive T cells (Sherman and
Chattopadhyay, 1993; Weber et al., 1995). The require-
ment of peptide plus MHC for allorecognition implies that
the diversity of peptides associated with MHC class I/II
antigens governs the characteristic alloantigenic diversity
of cells of different tissue lineages. Furthermore, Katz
and Sant (1994) have proposed that the role of processed
self-peptides may also explain why allorecognition can
appear highly cell-type speciﬁc. Thus, restrictions in the
ability to process and present peptides in association with
MHC will limit the intrinsic allogenicity of an APC.
This view is supported by several lines of evidence.
In an early report, Eckels et al. (1988) utilized a series of
HLA-DR1 transfected human ﬁbroblast lines to show that
these DR-1 transfectants were able to present a synthetic
inﬂuenza HA peptide to a panel of DR1 restricted T cell
clones but were also unable to process or present the
native intact virion. These same DR-1 transfectants were
able to induce alloproliferative responses in only one out
of a series of 25 speciﬁc alloreactive cloned T cell lines
that recognized distinct allotypic determinants associated
with HLA-DR1. An important implication from this study
was that antigen processing is required for the creation of
recognizable HLA-DR1 alloantigenic determinants on the
APC. More recently, Cotner et al. (1991) have shown that
HLA-DR3-speciﬁc T cell clones are unable to recognize
and respond to HLA-DR3
þ B cell lines possessing
mutations which prevent the formation of effective
peptide MHC Class II complexes.
In context of these ﬁndings, we reasoned an alternative
hypothesis for the observed lack of allogenicity of the W-1
cell line could be that cardiac myocytes possess a limited
ability to process and present antigenic peptides for
presentation by MHC resulting in the display of a number
of allotopes insufﬁcient to surpass a threshold leading to
alloactivation or anergy that could be measured by
conventional techniques. Such cell-type restrictions may
be the result of the presentation of a unique set(s) of
peptides processed from unique cell speciﬁc antigens, or
uniquely processed from “house-keeping” antigens
common to a broad variety of cell types, or both. It is
our belief that in highly differentiated cells, e.g. cardiac
myocytes, both of these types of restrictions may serve to
limit the repertoire of allogeneic MHC:peptide
conformers.
OnacellularlevelourstudyrevealsthatW-1scanpresent
the inﬂuenza A M1(58-66) peptide to HLA-A*0201
restricted CD8þ T cell clones that are speciﬁc for the M1
peptide, but their moderate capacity to process and present
theMIpeptideisdependentonpre-treatmentofthecellline
with IFN-g. This observation reveals three important
points. First, it is clear that W-1’s display a sufﬁcient
amount of MHC Class I (HLA-A2*0201) that is able to
bind and present exogenously loaded M1 peptide for
recognition by the HLA-A2-restricted PG CTL line.
Second, W-1’s also appear to display cell surface CSMs of
sufﬁcient quality and quantity to initiate antigen-speciﬁc
CTL responses. However, it can be argued that the
requirements for co-stimulation for productive allo-
responses by naive T cells and cytolytic responses from a
peptide-speciﬁc CTL line may differ. Third, pretreatment
ofW-1swithIFN-gpartiallyrestorestheirabilitytoprocess
the M1 peptide (Fig. 2C). The possibility that the (IFN-g)
induced expression of a novel cell surface molecule on W-
1s is responsible for the observed lysis is unlikely since
both untreated and IFN-g pretreated W-1s pulsed with the
MI peptide were able to be lysed equally well by PG CTLs
(Fig. 2).
IFN-g pretreatment did elevate gene expression for
TAP-1/2 and LMP-2 to levels comparable to those seen
constitutively in the EBV-PBL controls. However, mRNA
levels measured for MHC-1 and LMP-7 were only
moderately elevated. The modest increase in the
expression of these two genes might present a partial
explanation for the incomplete restoration of the ability to
process the inﬂuenza A M1 peptide for HLA-A2-
associated presentation. The precise role of LMP-2 and
LMP-7 in the processing of antigenic peptides remains
controversial. In 1992 reports of research from
two separate laboratories were published describing
reconstitution experiments in two different human
B lymphoblastoid cell lines, T2 (Momburg et al., 1992)
and 721.174 (Arnold et al., 1992), both having
homozygous deletions in the MHC Class II region
encompassing the genes encoding TAP-1/2 and LMP-2/7.
Each group demonstrated transfection with genes
encoding TAP-1/2 was both necessary and sufﬁcient for
surface expression of stable peptide MHC class I
complexes by these cell lines. Furthermore, Momburg
et al. (1992) demonstrated that reconstitution with
TAP-1/2 alone was sufﬁcient to restore the ability of the
T2 line to process and present the inﬂuenza M1(58-66)
peptide to an HLA-A2.1 restricted, M1 peptide-speciﬁc
CTL clone, Q66.9. However, Fehling et al. (1994) have
presented contradicting evidence by describing a knock-
out strain of mice lacking LMP-7 which showed a
markedly reduced ability to process and present the
endogenous HY antigen. Furthermore, more recently,
Cerundolo et al. (1995) were able to selectively restore the
ability to process the M1(58-66) peptide for presentation
to their M1-peptide speciﬁc CTL clone, JM 42, by
introducing TAP-1/2 and LMP-7 into the antigen
processing defective B cell line 721.174. These conﬂicting
data might be reconciled by a role in which LMP-7
(and LMP-2) is required for the creation of new sets of
antigenic peptides from viral (or self) antigens for
presentation by MHC class I. This might also explain
the partial restoration of W-1s to present the inﬂuenza A
M-1 peptide. However, the under expression of
PRESENTATION OF ANTIGENIC PEPTIDES BY CARDIAC MYOCYTES 223other (IFN-g) inducible components of the class I pathway
(in W-1s) that were not a part of this study
(e.g. chaperones, heat shock proteins, etc) may also be
involved Williams and Watts (1995) as well as problems
in gene translation.
Our investigation also revealed a signiﬁcant difference
in capacity between the class I and the class II antigen
processing and presentation pathways in the W-1 cell line.
Although W-1 cells respond to IFN-g by expressing
(SDS-stable) MHC class II (Ansari et al., 1994), such
pretreatment did not improve their ability to process or
present the immunodominant TT 830-843 peptide to
TT-speciﬁc HLA-DR3 restricted T cells (Fig. 1).
To interpret these results in terms of the efﬁciency of
gene expression within the MHC Class II locus, we
compared the levels of transcription and translation
relative to EBV-PBLs for selected genes involved in
antigen processing and presentation for class I (Fig. 6B)
and class II (Fig. 6A). When viewed this way, an
interesting picture emerges. The inability of IFN-g
pretreated W-1s to present antigenic peptides in
association with MHC class II, appears to be most
directly correlated with its relatively weak expression of
the genes encoding MHC class II and Ii. The levels of
expression of Ii and MHC class II by IFN-g W-1’s were
only 10–15% of those seen with EBV-PBL controls. This
ﬁnding was conﬁrmed at the level of gene transcription
and translation (Fig. 6A) as well as for cell surface
expression of MHC class II (by FMF-data not shown).
However, the ability of HLA-DR3 expressing W-1’s to
speciﬁcally bind P2 peptide was measured to be only 0.5%
of the amount able to bind to the HLA-DR3 expressing
EBV-PBL controls (Fig. 5C). Therefore, a probable
explanation for why IFN-g W-1s are unable to present P2
to TT-primed T cells is their inability to efﬁciently bind
the synthetic immunodominant TT (830-843) antigenic
peptide. Furthermore, a relatively low density of naked
MHC class II or the high afﬁnity of self peptides
associated with MHC Class II expressed on the cell
surface, which could account for such inefﬁcient binding,
could be a result of inefﬁcient antigen processing.
The results of our pulse-chase studies provide further
evidence for inefﬁcient antigen processing in IFN-g
W-1’s. We found the half-lives for all of the gene products
we examined within the MHC class II locus of W-1’s to be
at least 100% longer than the half-lives for corresponding
gene products found in EBV-PBL controls (Fig. 4B).
Furthermore, increasing the time for peptide or antigen
pulsing with IFN-g pretreated W-1’s did not reconstitute
their ability to induce antigen speciﬁc T cell activation
(data not shown). While these results do not preclude the
processing and presentation of antigenic peptides by
IFN-g W-1s, they do predict that the levels of processed
antigenic peptides presented in association with MHC
class I or class II would be proportionately lower than on
professional APCs, e.g. EBV-PBLs. Both Ii and DM are
involved in chaperoning nascent MHC Class II complexes
through early and late endocytic compartments, where
there may sample and acquire newly formed peptides
(Castellino and Germain, 1995; Sherman et al., 1995;
Sanderson et al., 1996). Restricted expression in these
critical components of the class II pathway, as witnessed
for W-1’s (Fig. 6A), would likely inﬂuence the array of
MHC II:peptide complexes (or allotopes) expressed on the
cell surface. Likewise, the relative under representation of
TAP-1/2 might limit the diversity of MHC 1: peptide
allogeneic determinants in W-1’s. It is also important to
note that the under expression of other genes (not a part of
this study) encoding proteases (e.g. cathepsin B and D),
chaperones (e.g. calnexin), or other components involved
in antigen processing for MHC class II may also
contribute to antigen presentation defects observed in
the W-1 cell line.
Another possible explanation for the lack of allogeni-
city observed in this cell line is insufﬁcient second
signaling due to under expression of critical
CAM’s/CSM’s. Although FHCM’s and W-1s do express
FIGURE 6 Comparison of transcription and translation of genes
involved in the class 1 and class II antigen processing and presentation
pathways. The levels of gene expression for IFN-g W-1s are presented as
a percentage of the corresponding levels in EBV-PBL controls. Gene
transcription is expressed as levels of mRNA determined by semi-
quantitative RT-PCR as described in “Materials and Methods” section.
Gene translation is expressed as levels of protein antigens
immunoprecipitated by the antibodies listed in Table IV as described.
(A) Comparison of transcription and translation of the class II pathway
genes MHC II, Ii and DMB. (B) Comparison of transcription and
translation of the class II pathway genes MHC I, TAP-2, LMP-7.
J.B. SUNDSTROM et al. 224important CSM’s, e.g. LFA-3 and ICAM-1, we have
shown that they do not constitutively express nor can they
beinducedtoexpresscriticalCSM’s,e.g.B7(Ansarietal.,
1994). One of the trivial explanation for the disparities in
the class I and II restricted responses of T cells to nominal
antigens by W-1s could be that the expression of critical
CSM’s by W-1 are more stringently required for MHC
class II restricted presentation than for class I. We have
demonstrated that CHO cell transfectants expressing
human HLA DR3 (but which do not express critical
CSM’s, e.g. LFA-3, ICAM-1, or B7) are able to present P2
peptide to HLA DR3
þ TT primed unfractionated PBMCs
but not puriﬁed T cells (unpublished results). In contrast,
IFN-g pretreated W-1s were unable to present P2 peptide
to either TT primed unfractionated PBMCs or puriﬁed
Tcells(Fig.1), suggesting that requisite second signals for
T cell responses to nominal antigen presented by W-1s can
not be delivered in trans by third party autologous
lymphocytes. Moreover, our unpublished data show that
even after reconstitution with GPI-anchored B7, MHC
class II expressing W-1 cells remain unable to present P2
peptide to TT primed responders. These ﬁndings lead us to
conclude that factors such as the diversity and density of
antigenic peptides as well as the afﬁnity of MHC/TCR
interactions, which collectively comprise ﬁrst signals
delivered in cognate interactions between T cells and
APCs, may all be inﬂuenced by intrinsic limitations in
antigen processing and presentation pathways in cardiac
myocytes. The signiﬁcance of second signals in the dialog
between host immune cells and donor cardiac myocytes in
models of chronic allograft rejection has been studied and
are the subject of a separate publication.
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